ClinicalTrials.gg

Program

Atrasentan

Also written as “Drug: Atrasentan”, “atrasentan” and “0.25 mg Atrasentan QD”.

Its studies are mostly in Glomerulonephritis, IGA · Prostatic Neoplasms · Renal Insufficiency, Chronic · Kidney Diseases · Diabetic Nephropathies, led by 3 companies.

Furthest: phase 3, since May 10, 200215 company-led studies, 4 open or runningNext primary completion: Apr 14, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott50 open or runningphase 3since May 10, 2002May 10, 2002none ahead
AbbVie50 open or runningphase 3since May 17, 2013Jun 11, 2009none ahead
Novartis54 open or runningphase 3since Sep 12, 2020Sep 12, 2020Apr 14, 2028phase 3 · NCT04573478

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2002First studies: 2 phase 3 studies in Prostatic NeoplasmsNew to AbbottAbbott · NCT00036556, NCT00036543
  2. Jun 3, 2002Phase 2 study in Prostatic NeoplasmsAbbott · NCT00038662 · 200 enrolled · United States, Canada
  3. Oct 3, 2002Phase 3 study in Prostatic NeoplasmsAbbott · NCT00046943 · United States
  4. Aug 4, 2005Phase 3 study in Prostatic NeoplasmsAbbott · NCT00127478 · 166 enrolled · United States, Canada, France and more
  5. Jun 11, 2009AbbVie's first study: phase 2 study in Renal Insufficiency, ChronicNew to AbbVieAbbVie · NCT00920764 · 92 enrolled · United States, Puerto Rico
  6. Apr 19, 2011Phase 2 study in Renal Insufficiency, ChronicAbbVie · NCT01356849 · 149 enrolled · United States, Canada, Puerto Rico and more
  7. Jul 20, 2011Phase 2 study in Renal Insufficiency, ChronicAbbVie · NCT01399580 · 48 enrolled · United States
  8. May 17, 2013Phase 3 study in Diabetic NephropathiesAbbVie · NCT01858532 · 5,107 enrolled
  9. Apr 14, 2014Phase 2 study in Kidney DiseasesAbbVie · NCT02118714 · 20 enrolled · United States, Germany, Italy and more
  10. Sep 12, 2020Novartis's first study: phase 3 study in Glomerulonephritis, IGANew to NovartisNovartis · NCT04573478 · 404 enrolled · United States, Argentina, Australia and more
  11. Sep 28, 2020Phase 2 study in Glomerulonephritis, IGANovartis · NCT04573920 · 103 enrolled · United States, Australia, Italy and more
  12. Apr 18, 2023Phase 2 study in Glomerulonephritis, IGANovartis · NCT05834738 · 54 enrolled · United States, Australia, Brazil and more
  13. Mar 23, 2026Phase 3 study in Glomerulonephritis, IGANovartis · NCT07498335 · 28 planned · United States, China, Colombia and more
  14. Sep 23, 2026Phase 3 study in Glomerulonephritis, IGANovartis · NCT07850752 · 340 planned

Ahead

  1. Apr 14, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANovartis · NCT04573478
  2. Sep 17, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANovartis · NCT07850752
  3. Sep 15, 2031Primary completion: phase 3 study in Glomerulonephritis, IGANovartis · NCT07498335

TargetBeta

EDNRA →read by rule
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule

Other programs on EDNRA

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437
sparsentanruletravere-therapeutics-incphase 49
zibotentanAstraZenecaphase 323
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07850752Glomerulonephritis, IGA3Not yet recruitingNovartisSep 17, 2028340
NCT07498335Glomerulonephritis, IGA · United States, China, Colombia and more3RecruitingNovartisSep 15, 203128
NCT05834738Glomerulonephritis, IGA · United States, Australia, Brazil and more2CompletedNovartisJun 30, 202554
NCT04573920Glomerulonephritis, IGA · United States, Australia, Italy and more2Active, not recruitingNovartisJul 2, 2024103
NCT04573478Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingNovartisApr 14, 2028404
NCT02118714Kidney Diseases · United States, Germany, Italy and more2CompletedAbbVieApr 18, 201820
NCT01858532Diabetic Nephropathies3TerminatedAbbVieMar 29, 20185,107
NCT01399580Renal Insufficiency, Chronic · United States2CompletedAbbVieSep 201248
NCT01356849Renal Insufficiency, Chronic · United States, Canada, Puerto Rico and more2CompletedAbbVieAug 2012149
NCT00920764Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedAbbVieApr 201092
NCT00127478Prostatic Neoplasms · United States, Canada, France and more3CompletedAbbott166
NCT00046943Prostatic Neoplasms · United States3CompletedAbbottJun 2007
NCT00038662Prostatic Neoplasms · United States, Canada2CompletedAbbott200
NCT00036556Prostatic Neoplasms · United States, Australia, Austria and more3CompletedAbbott941
NCT00036543Prostatic Neoplasms · United States, Australia, Austria and more3CompletedAbbott1,000

How it is read

Names in the registry

  • “Atrasentan”, 12 entries
  • “Drug: Atrasentan”, 1 entry
  • “atrasentan”, 1 entry
  • “0.25 mg Atrasentan QD”, 1 entry
  • “0.75 mg Atrasentan QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.